Pharmacokinetics of mycophenolic acid and its glucuronide after a single and multiple oral dose of mycophenolate mofetil in Chinese renal transplantation recipients

被引:4
|
作者
Liang, M. Z.
Lu, Y. P.
Nan, F.
Li, Y. P. [1 ]
机构
[1] Sichuan Univ, W China Hosp, Inst Organ Transplantat, Chengdu 610041, Peoples R China
[2] Sichuan Univ, W China Hosp, Div Clin Pharmacol, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
D O I
10.1016/j.transproceed.2006.06.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purposes. To compare the pharmacokinetic parameters of mycophenolic acid (MPA) and mycophenolic acid glucuronide (MPAG) after single and multiple oral administration of mycophenolate mofetil (MMF) in Chinese renal transplant patients with those of recipients in other countries. Methods. Twelve Chinese renal transplant patients after an overnight fast received a single 1-g dose of MMF before renal transplantation. Thereafter the patients received 1 g MMF twice a day up to and on the day 12 after renal transplantation. The concentrations of MPA and MPAG were simultaneously measured by RP-HPLC. The concentration-time data were examined with Drug and Statistics pharmacokinetic software. Using paired samples t test (self-contrast) with SPSS statistical software (alpha = 0.05), we compared the pharmacokinetic parameters between single and multiple doses. Results and discussions. The MPA concentration-time profiles were fitted to a two-compartment open model; MPAG concentration-time profiles were fitted to a single-compartment open model. Compared with the literature reports, the main pharmacokinetic parameters of MPA and MPAG shown by our research revealed some differences. The parent drug MMF was undetectable in plasma during oral administration. A secondary peak of MPA occurred at 6 to 10 hours, which was attributed to enterohepatic recirculation. There was significant variation in MPA and MPAG plasma concentration-time data among subjects. It is suggested that therapeutic drug monitoring should be applied for dosage optimization.
引用
收藏
页码:2044 / 2047
页数:4
相关论文
共 50 条
  • [1] Pharmacokinetics of mycophenolic acid after a single and multiple oral doses of mycophenolate mofetil in chinese renal transplant recipients
    Liang, MZ
    Lu, YP
    Nan, F
    Yu, Q
    Qin, YP
    Zou, YG
    [J]. TRANSPLANTATION PROCEEDINGS, 2004, 36 (07) : 2065 - 2067
  • [2] PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS RECEIVING ORAL MYCOPHENOLATE MOFETIL
    Jacobs, Bart
    Cornelissen, Marlies
    Aarnoutse, Rob
    Schreuder, Michiel
    Bruggemann, Roger
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (05) : 829 - 829
  • [3] Population Pharmacokinetics of Mycophenolic Acid and Its Main Glucuronide Metabolite: Comparison Between Chinese and Caucasian Healthy Subjects Receiving a Single Oral Dose of Mycophenolate Mofetil
    Ling, Jing
    Jiao, Zheng
    Jiang, Qiudi
    Shi, Jun
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S11 - S11
  • [4] Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil
    Li, H.
    Mager, D. E.
    Sandmaier, B. M.
    Maloney, D. G.
    Bemer, M. J.
    McCune, J. S.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (04): : 393 - 402
  • [5] Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolites in Stable Adult Liver Transplant Recipients With Renal Dysfunction on a Low-Dose Calcineurin Inhibitor Regimen and Mycophenolate Mofetil
    Beckebaum, Susanne
    Armstrong, Victor W.
    Cicinnati, Vito Rosario
    Streit, Frank
    Klein, Christian Georg
    Gerken, Guido
    Paul, Andreas
    Oellerich, Michael
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (02) : 205 - 210
  • [6] Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil
    Kuypers, DRJ
    Vanrenterghem, Y
    Squifflet, JP
    Mourad, M
    Abramowicz, D
    Oellerich, M
    Armstrong, V
    Shipkova, M
    Daems, J
    [J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (05) : 609 - 622
  • [7] Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients
    Armstrong, VW
    Tenderich, G
    Shipkova, M
    Parsa, A
    Koerfer, R
    Schröder, H
    Oellerich, M
    [J]. THERAPEUTIC DRUG MONITORING, 2005, 27 (03) : 315 - 321
  • [8] Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus
    Xu, Lu-yang
    Jiao, Zheng
    Liu, Fei-yan
    Qiu, Xiao-yan
    Ji, Li
    Zhang, Ming
    [J]. THERAPEUTIC DRUG MONITORING, 2018, 40 (05) : 572 - 580
  • [9] Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil
    Ling, Jing
    Shi, Jun
    Jiang, Qiudi
    Jiao, Zheng
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (01) : 95 - 106
  • [10] Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil
    Jing Ling
    Jun Shi
    Qiudi Jiang
    Zheng Jiao
    [J]. European Journal of Clinical Pharmacology, 2015, 71 : 95 - 106